Scancell Holdings Plc Notice of AGM

TIDMSCLP

RNS Number : 7447K

Scancell Holdings Plc

23 September 2016

Scancell Holdings Plc

Notice of AGM

Amendment

Scancell Holdings plc ('Scancell' or the 'Company'), the developer of novel immunotherapies for the treatment of cancer, will host its Annual General Meeting on Tuesday 18 October 2016.

AGM details are as follows:

 
Date:      Tuesday 18 October, 
            2016 
 
  Time:      2.30pm 
 
  Venue:     The Kassam Stadium 
             Grenoble Road 
             Oxford 
             OX4 4XP

For Further Information:

 
 Dr John Chiplin, Executive 
  Chairman                                          +1 858 900 2646 
  Dr Richard Goodfellow,       Scancell Holdings     +44 (0) 20 3727 
  CEO                           Plc                  1000 
 
 Freddy Crossley (Corporate                         +44 (0) 20 7886 
  Finance)                                           2500 
  Tom Salvesen (Corporate      Panmure Gordon        +44 (0) 20 7886 
  Broking)                      & Co                 2500 
 
                                                    +44 (0) 20 3727 
 Mo Noonan/Simon Conway        FTI Consulting        1000

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody(R) and Moditope(R) technology platforms.

Scancell's first ImmunoBody(R), SCIB1 is being developed for the treatment of melanoma. Data from the Phase 1/2 clinical trial demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects. In patients with resected disease there is increasing evidence to suggest that SCIB1 may delay or prevent disease recurrence.

Scancell's ImmunoBody(R) vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system where inflammation is stimulated at the tumour site and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Pre-clinical data on a combination of SCIB1 or SCIB2 and checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune checkpoint pathways) have shown enhanced tumour destruction and significantly longer survival times than when either treatment was used alone.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4+ T cells that destroy tumours without toxicity. The Directors believe that the Moditope(R) platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NOAPGUBGBUPQGQW

(END) Dow Jones Newswires

September 23, 2016 12:24 ET (16:24 GMT)

Scancell (LSE:SCLP)
Historical Stock Chart
From Apr 2024 to May 2024